Morphine administration to pregnant rabbits: effect on fetal growth and lung development.
Morphine was injected subcutaneously in doses of 2.5 to 10 mg/kg every 6 hours into pregnant rabbits from early pregnancy until delivery by hysterotomy on the 27th, 28th or 29th day. Pregnant control animals received 0.9% NaC1 injections. Abortions occurred in 34% of the morphine-treated does as a doserelated effect and in 6.5% of the controls. In preserved pregnancies the prevalence of intrauterine death was identical in both samples. Fetuses of treated animals weighed significantly less than those of the controls.However, the normally present effect of intrauterine position on fetal growth was not altered in fetuses of treated animals, so that growth-retarded as well as normal fetuses weighed more when located in the ovarium rather than the cervical portion of the uterus. The fetal lungs were inflated to 35 cm H2O and the remaining air at a deflation pressure of 10 cm H2O (V10) was determined as a measure of lung stability. There were no differences in this indicator of fetal lung maturity between fetuses of treated and control animals. It was found that the lecithin/sphingomyelin (L/S) ratio in the amniotic fluid of rabbits does not correlate with lung maturity; there were no differences between fetuses of treated and control animals. Morphine, when administered to pregnant rabbits does not accelerate fetal lung development. Therefore, the observed reduction in the incidence of respiratory distress syndrome in infants of heroin-addicted women has no direct equivalent in this animal model.
D000022:Abortion, Spontaneous / Q000139:chemically induced; D000653:Amniotic Fluid / Q000032:analysis; D000818:Animals; D001724:Birth Weight / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D010064:Embryo Implantation; D005260:Female; D005313:Fetal Death; D005333:Fetus / Q000187:drug effects*; D005865:Gestational Age; D006801:Humans; D007279:Injections, Subcutaneous; D008168:Lung / Q000254:growth & development*; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology; D010713:Phosphatidylcholines / Q000032:analysis; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D011817:Rabbits; D012115:Residual Volume; D013109:Sphingomyelins / Q000032:analysis; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced
D010713:Phosphatidylcholines; D013109:Sphingomyelins; D009270:Naloxone; D009020:Morphine